NASH

[Cell Death & Differentiation] Scientists found that liver-specific deletion of Ssu72 phosphatase in mice, leads to a high incidence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, but not hepatocellular carcinoma.

[Scientific Reports] Scientists profiled 17,810 non-parenchymal cells derived from six healthy human livers, which enabled the identification of potential intercellular signaling axes and master regulators responsible for the activation of hepatic stellate cells during fibrogenesis.

[Liver International] Scientists summarize cross-sectional human studies using liver biopsy/lipidomics and proton magnetic resonance spectroscopy to characterize hepatic lipid composition in people with obesity and related metabolic disease.

[POXEL SA] POXEL SA announced the completion of enrollment in DESTINY-1, a dose-ranging Phase II trial evaluating PXL065 for the treatment of non-alcoholic steatohepatitis (NASH).

[Journal of Hepatology] By performing a liver proteomic analysis from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, investigators identified autophagy-related gene 3 (ATG3) as a new target downstream of p63.

[Hepatology] Researchers identified a transcription factor Zinc Fingers and Homeoboxes 2 (ZHX2) in hepatocytes as a protective factor against steatohepatitis. Hepatocyte-specific ablation of ZHX2 exacerbated NASH-related phenotypes in mice, including lipid accumulation, enhanced inflammation, and hepatic fibrosis.